Goldman Sachs
SPRO icon

Goldman Sachs’s Spero Therapeutics SPRO Stock Holding History

Goldman Sachs’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-55,438
Closed -$111K – 6249
2022
Q3 		$111K Sell
55,438
-247,763
-82% -$246K ﹤0.01% 5663
2022
Q2 		$225K Buy
303,201
+161,775
+114% +$470K ﹤0.01% 5588
2022
Q1 		$1.23M Buy
141,426
+2,815
+2% +$28.8K ﹤0.01% 4657
2021
Q4 		$2.22M Buy
138,611
+1,032
+0.8% +$16.4K ﹤0.01% 4171
2021
Q3 		$2.53M Buy
137,579
+1,317
+1% +$21.1K ﹤0.01% 3969
2021
Q2 		$1.9M Sell
136,262
-119,538
-47% -$1.67M ﹤0.01% 4254
2021
Q1 		$3.77M Buy
255,800
+214,179
+515% +$3.77M ﹤0.01% 3407
2020
Q4 		$807K Buy
41,621
+10,256
+33% +$160K ﹤0.01% 4337
2020
Q3 		$350K Sell
31,365
-20,593
-40% -$244K ﹤0.01% 4657
2020
Q2 		$703K Buy
51,958
+24,696
+91% +$277K ﹤0.01% 4188
2020
Q1 		$220K Sell
27,262
-4,284
-14% -$37.8K ﹤0.01% 4661
2019
Q4 		$303K Buy
31,546
+17,740
+128% +$191K ﹤0.01% 4742
2019
Q3 		$146K Sell
13,806
-8,171
-37% -$86.1K ﹤0.01% 4909
2019
Q2 		$253K Buy
21,977
+9,285
+73% +$112K ﹤0.01% 4687
2019
Q1 		$163K Sell
12,692
-3,505
-22% -$37.2K ﹤0.01% 4846
2018
Q4 		$100K Buy
+16,197
New +$131K ﹤0.01% 4997

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs's SPRO Position: Q4 2022 in Review

Goldman Sachs sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 55,438 shares — an estimated $111K sold.

Goldman Sachs first reported a position in SPRO in Q4 2018 and held it in 16 quarters. The position peaked at $3.77M in Q1 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • Goldman Sachs reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 55,438 Spero Therapeutics shares in Q4 2022, an estimated $111K.
  • Goldman Sachs first reported a position in Spero Therapeutics in Q4 2018 and held it in 16 quarters.
  • Goldman Sachs's Spero Therapeutics position peaked at $3.77M in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.